| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner | 10% Owner
4 companies
Peter Thiel is Director at PLTR and has filed Form 4s across 4 companies. Peter Thiel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.4B at current prices.
Historically, Peter Thiel's trades have earned a below-average insider score of 34/100 across 13 rated trades. Over a 12-month horizon, 8.3% of those trades were profitable, with an average 12-month return of -86.2%.
The biggest single holding is PLTR (~$2.4B) as Director. The PLTR filings lean toward selling, a net 97,982,596 shares.
Peter Thiel has 32 Form 4 filings on record from May 2015 to March 2026, across 4 companies: Director at Palantir Technologies (PLTR), 2020–2026; Director at META, 2015–2022; 10% Owner at Chemomab Therapeutics (CMMB), 2021, and 1 more.
The 157 reported transactions were 105 open-market sales, 28 conversions, 9 option exercises and 4 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $60.0M and 17 sales worth about $2.8B.
The only open-market purchase was 3,000,000 shares of ABCL at an average $20.00 on December 15, 2020, about $60.0M.
The largest open-market sale was 16,178,415 shares of PLTR at an average $36.90 on September 26, 2024, about $597.0M. Twelve months later PLTR was up 379%.
All 5 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | PLTR Palantir Technologies Inc. | Director | Sell10b5-1 | 2,000,000 | $144.85 | $289,707,507.04 | -12.7% | +10.7% | - | |
| Oct 1, 2024 | PLTR Palantir Technologies Inc. | Director | Sell10b5-1 | 12,412,322 | $36.85 | $457,353,247.64 | -26.6% | +111.7% | +407.3% | |
| Sep 26, 2024 | PLTR Palantir Technologies Inc. | Director | Sell10b5-1 | 16,178,415 | $36.90 | $597,001,788.14 | -25.7% | +121.4% | +378.6% | |
| May 10, 2024 | PLTR Palantir Technologies Inc. | Director | Sell10b5-1 | 12,955,244 | $21.11 | $273,490,548.44 | -45.2% | +42.1% | +469.4% | |
| Mar 12, 2024 | PLTR Palantir Technologies Inc. | Director | Sell10b5-1 | 7,044,756 | $24.79 | $174,615,999.27 | -9.0% | -6.4% | +238.7% | |
| Aug 13, 2021 | PLTR Palantir Technologies Inc. | Director, 10% Owner | Sell | 3,262 | $25.00 | $81,550.00 | -100% | -7.7% | -60.2% | |
| Mar 16, 2021 | CMMB Chemomab Therapeutics Ltd. | 10% Owner | Buy | 230,536 | $0.00 | - | +26.3% | -70.7% | -94.4% | |
| Feb 18, 2021 | PLTR Palantir Technologies Inc. | Director, 10% Owner | Sell | 20,003,915 | $25.23 | $504,783,221.27 | - | - | - | |
| Dec 15, 2020 | ABCL Abcellera Biologics Inc. | Director | Buy | 3,000,000 | $20.00 | $60,000,000.00 | +41.8% | - | - | |
| Oct 2, 2020 | PLTR Palantir Technologies Inc. | Director, 10% Owner | Sell | 1,875,981 | $10.40 | $19,510,549.85 | -100.0% | - | - |